ASND

Ascendis Pharma A/S

Healthcare · $14.2B market cap

We can't put a fair value on ASND right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

3 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?

Equity per share growth19.4% a year✓

Sales growth61.0% a year✓

Free cash flow growth19.6% a year✓

Return on invested capital-47.2%✗

Follow ASND

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds ASND right now. In Q2 2026, 1 sold out. Who we track

Moves in Q2 2026

Sold out: Polen Capital Management

Insider activity

Since Sep 2, 2026: no open-market purchases, 2 sales worth $873K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Sales

Bodenhoff Mads

SVP & PAO · 2026-09-08

Sold

$811K

HOLTUG LARS

director · 2026-09-02

Sold

$62K

Other filings

Bodenhoff Mads

SVP & PAO · 2026-09-08

Option exercise

$330K

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon…

Biotechnology